BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28739201)

  • 1. Neonatal detection of Aicardi Goutières Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots.
    Armangue T; Orsini JJ; Takanohashi A; Gavazzi F; Conant A; Ulrick N; Morrissey MA; Nahhas N; Helman G; Gordish-Dressman H; Orcesi S; Tonduti D; Stutterd C; van Haren K; Toro C; Iglesias AD; van der Knaap MS; Goldbach Mansky R; Moser AB; Jones RO; Vanderver A
    Mol Genet Metab; 2017 Nov; 122(3):134-139. PubMed ID: 28739201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aicardi-Goutières syndrome may present with positive newborn screen for X-linked adrenoleukodystrophy.
    Tise CG; Morales JA; Lee AS; Velez-Bartolomei F; Floyd BJ; Levy RJ; Cusmano-Ozog KP; Feigenbaum AS; Ruzhnikov MRZ; Lee CU; Enns GM
    Am J Med Genet A; 2021 Jun; 185(6):1848-1853. PubMed ID: 33683010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of newborn screening for X-linked adrenoleukodystrophy based on liquid chromatography-tandem mass spectrometry method for detection of C26:0-lysophosphatidylcholine in dried blood spots: Results from 43,653 newborns in a southern Chinese population.
    Tang C; Tang F; Cai Y; Tan M; Liu S; Xie T; Jiang X; Huang Y
    Clin Chim Acta; 2024 Jan; 552():117653. PubMed ID: 37977233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of C26:0-carnitine and C26:0-lysophosphatidylcholine as diagnostic markers in dried blood spots from newborns and patients with adrenoleukodystrophy.
    Huffnagel IC; van de Beek MC; Showers AL; Orsini JJ; Klouwer FCC; Dijkstra IME; Schielen PC; van Lenthe H; Wanders RJA; Vaz FM; Morrissey MA; Engelen M; Kemp S
    Mol Genet Metab; 2017 Dec; 122(4):209-215. PubMed ID: 29089175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of X-Linked Adrenoleukodystrophy Newborn Screening in North Carolina.
    Lee S; Clinard K; Young SP; Rehder CW; Fan Z; Calikoglu AS; Bali DS; Bailey DB; Gehtland LM; Millington DS; Patel HS; Beckloff SE; Zimmerman SJ; Powell CM; Taylor JL
    JAMA Netw Open; 2020 Jan; 3(1):e1920356. PubMed ID: 32003821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streamlined determination of lysophosphatidylcholines in dried blood spots for newborn screening of X-linked adrenoleukodystrophy.
    Turgeon CT; Moser AB; Mørkrid L; Magera MJ; Gavrilov DK; Oglesbee D; Raymond K; Rinaldo P; Matern D; Tortorelli S
    Mol Genet Metab; 2015 Jan; 114(1):46-50. PubMed ID: 25481105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow injection ionization-tandem mass spectrometry-based estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy.
    Natarajan A; Christopher R; Netravathi M; Bhat MD; Chandra SR
    Clin Chim Acta; 2019 Aug; 495():167-173. PubMed ID: 30980791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible.
    Theda C; Gibbons K; Defor TE; Donohue PK; Golden WC; Kline AD; Gulamali-Majid F; Panny SR; Hubbard WC; Jones RO; Liu AK; Moser AB; Raymond GV
    Mol Genet Metab; 2014 Jan; 111(1):55-7. PubMed ID: 24268529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid chromatography-tandem mass spectrometry method for estimation of a panel of lysophosphatidylcholines in dried blood spots for screening of X-linked adrenoleukodystrophy.
    Natarajan A; Christopher R; Netravathi M; Bhat M; Chandra SR
    Clin Chim Acta; 2018 Oct; 485():305-310. PubMed ID: 30018013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved analysis of C26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for X-linked adrenoleukodystrophy newborn screening.
    Haynes CA; De Jesús VR
    Clin Chim Acta; 2012 Aug; 413(15-16):1217-21. PubMed ID: 22503909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.
    Rice GI; Forte GM; Szynkiewicz M; Chase DS; Aeby A; Abdel-Hamid MS; Ackroyd S; Allcock R; Bailey KM; Balottin U; Barnerias C; Bernard G; Bodemer C; Botella MP; Cereda C; Chandler KE; Dabydeen L; Dale RC; De Laet C; De Goede CG; Del Toro M; Effat L; Enamorado NN; Fazzi E; Gener B; Haldre M; Lin JP; Livingston JH; Lourenco CM; Marques W; Oades P; Peterson P; Rasmussen M; Roubertie A; Schmidt JL; Shalev SA; Simon R; Spiegel R; Swoboda KJ; Temtamy SA; Vassallo G; Vilain CN; Vogt J; Wermenbol V; Whitehouse WP; Soler D; Olivieri I; Orcesi S; Aglan MS; Zaki MS; Abdel-Salam GM; Vanderver A; Kisand K; Rozenberg F; Lebon P; Crow YJ
    Lancet Neurol; 2013 Dec; 12(12):1159-69. PubMed ID: 24183309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.
    Crow YJ; Chase DS; Lowenstein Schmidt J; Szynkiewicz M; Forte GM; Gornall HL; Oojageer A; Anderson B; Pizzino A; Helman G; Abdel-Hamid MS; Abdel-Salam GM; Ackroyd S; Aeby A; Agosta G; Albin C; Allon-Shalev S; Arellano M; Ariaudo G; Aswani V; Babul-Hirji R; Baildam EM; Bahi-Buisson N; Bailey KM; Barnerias C; Barth M; Battini R; Beresford MW; Bernard G; Bianchi M; Billette de Villemeur T; Blair EM; Bloom M; Burlina AB; Carpanelli ML; Carvalho DR; Castro-Gago M; Cavallini A; Cereda C; Chandler KE; Chitayat DA; Collins AE; Sierra Corcoles C; Cordeiro NJ; Crichiutti G; Dabydeen L; Dale RC; D'Arrigo S; De Goede CG; De Laet C; De Waele LM; Denzler I; Desguerre I; Devriendt K; Di Rocco M; Fahey MC; Fazzi E; Ferrie CD; Figueiredo A; Gener B; Goizet C; Gowrinathan NR; Gowrishankar K; Hanrahan D; Isidor B; Kara B; Khan N; King MD; Kirk EP; Kumar R; Lagae L; Landrieu P; Lauffer H; Laugel V; La Piana R; Lim MJ; Lin JP; Linnankivi T; Mackay MT; Marom DR; Marques Lourenço C; McKee SA; Moroni I; Morton JE; Moutard ML; Murray K; Nabbout R; Nampoothiri S; Nunez-Enamorado N; Oades PJ; Olivieri I; Ostergaard JR; Pérez-Dueñas B; Prendiville JS; Ramesh V; Rasmussen M; Régal L; Ricci F; Rio M; Rodriguez D; Roubertie A; Salvatici E; Segers KA; Sinha GP; Soler D; Spiegel R; Stödberg TI; Straussberg R; Swoboda KJ; Suri M; Tacke U; Tan TY; te Water Naude J; Wee Teik K; Thomas MM; Till M; Tonduti D; Valente EM; Van Coster RN; van der Knaap MS; Vassallo G; Vijzelaar R; Vogt J; Wallace GB; Wassmer E; Webb HJ; Whitehouse WP; Whitney RN; Zaki MS; Zuberi SM; Livingston JH; Rozenberg F; Lebon P; Vanderver A; Orcesi S; Rice GI
    Am J Med Genet A; 2015 Feb; 167A(2):296-312. PubMed ID: 25604658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aicardi goutières syndrome is associated with pulmonary hypertension.
    Adang LA; Frank DB; Gilani A; Takanohashi A; Ulrick N; Collins A; Cross Z; Galambos C; Helman G; Kanaan U; Keller S; Simon D; Sherbini O; Hanna BD; Vanderver AL
    Mol Genet Metab; 2018 Dec; 125(4):351-358. PubMed ID: 30219631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).
    de Barcelos IP; Woidill S; Gavazzi F; Modesti NB; Sevagamoorthy A; Vanderver A; Adang L
    Mol Genet Metab; 2024 May; 142(1):108346. PubMed ID: 38368708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features.
    Piccoli C; Bronner N; Gavazzi F; Dubbs H; De Simone M; De Giorgis V; Orcesi S; Fazzi E; Galli J; Masnada S; Tonduti D; Varesio C; Vanderver A; Vossough A; Adang L
    Pediatr Neurol; 2021 Feb; 115():1-6. PubMed ID: 33307271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and neuroradiologic variability of Aicardi-Goutiéres syndrome: Two siblings with RNASEH2C mutation and a boy with TREX1 mutation.
    Uyur Yalçın E; Maraş Genç H; Kara B
    Turk J Pediatr; 2015; 57(5):504-8. PubMed ID: 27411419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aicardi-Goutières syndrome.
    Crow YJ
    Handb Clin Neurol; 2013; 113():1629-35. PubMed ID: 23622384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a panel of very long-chain lysophosphatidylcholines and acylcarnitines for screening of X-linked adrenoleukodystrophy in China.
    Tian GL; Xu F; Jiang K; Wang YM; Ji W; Zhuang YP
    Clin Chim Acta; 2020 Apr; 503():157-162. PubMed ID: 31978407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory myopathy in a patient with Aicardi-Goutières syndrome.
    Tumienė B; Voisin N; Preikšaitienė E; Petroška D; Grikinienė J; Samaitienė R; Utkus A; Reymond A; Kučinskas V
    Eur J Med Genet; 2017 Mar; 60(3):154-158. PubMed ID: 28089741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nationwide survey of Aicardi-Goutières syndrome patients identifies a strong association between dominant TREX1 mutations and chilblain lesions: Japanese cohort study.
    Abe J; Nakamura K; Nishikomori R; Kato M; Mitsuiki N; Izawa K; Awaya T; Kawai T; Yasumi T; Toyoshima I; Hasegawa K; Ohshima Y; Hiragi T; Sasahara Y; Suzuki Y; Kikuchi M; Osaka H; Ohya T; Ninomiya S; Fujikawa S; Akasaka M; Iwata N; Kawakita A; Funatsuka M; Shintaku H; Ohara O; Ichinose H; Heike T
    Rheumatology (Oxford); 2014 Mar; 53(3):448-58. PubMed ID: 24300241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.